Purpose: CTLA-4 was the first inhibitory immune checkpoint to be identified. Two monoclonal antibodies, ipilimumab (IgG1) and tremelimumab (IgG2), which block the function of CTLA-4, have demonstrated durable clinical activity in a subset of patients with advanced solid malignancies by augmenting effector T cell-mediated immune responses. Studies in mice suggest that anti-CTLA-4 monoclonal antibodies may also selectively deplete intratumoral FOXP3 + regulatory T cells via an Fc-dependent mechanism. However, it is unclear whether the depletion of FOXP3 + cells occurs in cancer patients treated with anti-CTLA-4 therapies. Experimental Design: Quantitative immunohistochemistry was used to evaluate the densities of intratumoral CD4 + , CD8 + and FOXP3 + cells in stage-matched melanoma (N=19), prostate cancer (N=17) and bladder cancer (N=9) samples treated with ipilimumab and in paired melanoma tumors (N=18) treated with tremelimumab. These findings were corroborated with multiparametric mass cytometry analysis of tumor infiltrating cells from paired fresh melanoma tumors (N=5) treated with ipilimumab. Results: Both ipilimumab and tremelimumab increase infiltration of intratumoral CD4 + and CD8 + cells without significantly changing or depleting FOXP3 + cells within the tumor microenvironment. Conclusions: Anti-CTLA-4 immunotherapy does not deplete FOXP3 + cells in human tumors, which suggests that their efficacy could be enhanced by modifying the Fc portions of the monoclonal antibodies to enhance Fc-mediated depletion of intratumoral regulatory T cells. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.Ribas, J. Wargo, L. Vence, J. Allison and P. Sharma Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.
Statement of translational relevance
In preclinical murine models, anti-CTLA-4 monoclonal antibodies promote cancer regression by increasing the frequency of effector T cells within the tumor microenvironment and selectively depleting intratumoral regulatory T cells via an Fcdependent mechanism. However, it is unclear whether this occurs in cancer patients treated with anti-CTLA-4 therapies. Herein, we show that treatment with IgG1 ipilimumab and IgG2 tremelimumab monoclonal antibodies, which have distinct FcγRmediated mechanisms, increase the density of intratumoral CD4 and CD8 T cells, and do not deplete FOXP3 + Tregs across different human tumors. These data suggest that there is an opportunity to improve the clinical efficacy of anti-CTLA-4 immunotherapies by modifying the monoclonal antibodies to promote the depletion of intratumoral regulatory T cells.
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Author Manuscript Published OnlineFirst on July 27, 2018; DOI: 10.1158/1078-0432.CCR- Introduction Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) is an inhibitory immune checkpoint receptor that plays a crucial role in modulating T cell responses (1, 2) . In preclinical studies, transient blockade of CTLA-4 resulted in tumor eradication and durable anti-tumor immunity (3) . These findings translated into the clinical development of fully human monoclonal antibodies (mAbs) against CTLA-4, including ipilimumab and tremelimumab; an approach termed immune checkpoint blockade that has proven to be a paradigm shift in cancer therapy (4) .
Initial preclinical studies primarily implicated effector T (Teff) cells in mediating the therapeutic activity of CTLA-4 blockade (1, 3) ; however, later studies demonstrated the contribution of both the effector and regulatory T cell compartments in promoting antitumor responses (5) (6) (7) (8) (9) (10) . Regulatory T cells (Tregs) maintain immune cell homeostasis and suppress anti-tumor immune responses. They express CD4, CD25 and forkhead box protein P3 (FOXP3), a transcription factor required for their function. In addition, Tregs constitutively express high levels of CTLA-4 on their surface (11) (12) (13) , and FOXP3 is known to direct CTLA-4 transcription (14, 15) , which led to the hypotheses that CTLA-4 blockade may impair the suppressive activity of Tregs or directly deplete Tregs via antibody-dependent cell-mediated cytotoxicity (ADCC) (16, 17) .
More recent preclinical murine studies demonstrated that the therapeutic activity of anti-CTLA-4 mAbs (clones 9D9, 9H10 and 4F10) was dependent upon selective depletion of intratumoral Tregs via ADCC. In these studies, tumor regression was associated with an increase in the intratumoral Teff to Treg cell ratio, due to the preferential expansion of Teff cells and the selective depletion of Tregs (5, 7) . Treg depletion was attributed to tumor-infiltrating macrophages expressing the Fc-receptor, FcγRIV (5) . A murine anti-CTLA-4 mAb containing an IgG2a (clone 9D9) constant region was shown to exhibit enhanced ADCC-dependent intratumoral Treg depletion when compared to IgG2b and IgG1 murine anti-CTLA-4 mAbs (7) .
Ipilimumab, the first fully human IgG1 mAb against CTLA-4, demonstrated durable clinical activity and prolonged survival in patients with advanced melanoma (18, 19) . It has also been tested in other cancer types including non-small-cell lung cancer, renal cell carcinoma, urothelial carcinoma and prostate cancer (4) . Similarly tremelimumab, an anti-CTLA-4 IgG2 mAb, has also been clinically studied across several tumor types (20) .
The humanized IgG1 mAb isotype binds to most human Fc receptors, and it has the ability to induce ADCC; whereas, the IgG2 isotype is known to have less ADCC activity (21) . Clinical studies have been unclear in defining the role of IgG1 ipilimumab and IgG2 tremelimumab in depleting intratumoral Tregs in human cancers (9, 22) . 
Materials and Methods

Patient material
Formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from a cohort of stage-matched untreated and ipilimumab-treated primary prostate cancer patients (N=17), primary bladder cancer patients (N=9) and metastatic melanoma patients The data was analyzed by gating on CD45 + live singlets using ViSNE (23) and FlowJo.
Statistical analysis
The statistical analysis for each immune subset between the untreated versus treated cohorts was performed using Mann-Whitney unpaired t-test for the unpaired tumor Preclinical and early clinical studies suggest that CTLA-4 blockade promotes anti-tumor activity by increasing the frequency of intratumoral Teff cells (5, 7, 8, 10, 24, 25) . To confirm these findings using tissues obtained from patients treated with two different anti-CTLA-4 mAbs, we examined the immune profile of melanoma tumors by immunohistochemistry (IHC). Our data demonstrate that both ipilimumab ( Fig. 1A and   Supplementary Fig. S1A ) and tremelimumab ( Fig. 1B) significantly increased the intratumoral densities of both CD4 + and CD8 + cells. Similar results have been reported in human melanoma upon treatment with tremelimumab (26) . Consistent with these findings, we observed increased densities of intratumoral CD4 + and CD8 + cells in bladder and prostate tumors obtained from patients treated with ipilimumab ( Supplementary   Fig. S2A and S2B ).
Anti-CTLA-4 immunotherapy does not deplete intratumoral FOXP3 + cells in human cancers.
As it is postulated that human IgG1 mAbs promote ADCC to a greater extent than IgG2 (21), we evaluated the potential differential effects of ipilimumab (IgG1) and tremelimumab (IgG2) on the densities of FOXP3 + cells in tumor tissues from patients with advanced melanoma. Surprisingly, both ipilimumab ( Fig. 2A and Supplementary   Fig. S3 ) and tremelimumab (Fig. 2B) biopsies from two patients with melanoma, which were negative for FOXP3 + cells, showed FOXP3 + cellular infiltration post-tremelimumab treatment (Fig. 2B) .
Furthermore, in bladder and prostate tumors obtained from patients treated with ipilimumab, there was no reduction in intratumoral FOXP3 + cells ( Fig. 3 and   Supplementary Fig. S3 ). Taken together, the data demonstrate that both ipilimumab and tremelimumab, despite having two different IgG isotypes with potentially different mechanisms of action, similarly augment the densities of intratumoral CD4 + and CD8 + cells, but do not deplete FOXP3 + cells.
Presence of tumor-associated macrophages in baseline and ipilimumab-treated biopsies
In humans, ADCC is primarily mediated by FcγRIIIA (CD16a) (27) , which is expressed on macrophages and natural killer (NK) cells. The lack of intratumoral Treg depletion following treatment with ipilimumab could be attributable to a paucity of macrophages or NK cells and/or FcγRIIIA expression within the tumor microenvironment. Therefore, we sought to evaluate the effect of ipilimumab on intratumoral CD68 + macrophages in advanced melanoma patients. Compared to intratumoral CD4 + and CD8 + cell densities, there was considerable infiltration of CD68 + macrophage in the untreated tumor samples, which did not significantly change following treatment with ipilimumab ( Fig. 4) 
Discussion
Anti-CTLA-4 immunotherapy has demonstrated significant anti-tumor activity in preclinical and clinical studies (3, 6, 18, 19, 28) , and it has emerged as a paradigm shift in cancer therapy. Although the effect of CTLA-4 blockade on Teff cells has been well established, its effect on human FOXP3 + Tregs within the tumor microenvironment remains unclear. While some studies report a decrease in the frequency of circulating or intratumoral Tregs (5, 7, 9, 29, 30) , other studies did not result in Treg depletion following anti-CTLA-4 treatment (11, 25, 26, 31, 32) . The current study has been undertaken to gain a better understanding of the effect of anti-CTLA-4 therapy on intratumoral FOXP3 + Tregs in human cancers.
Preclinical studies have reported that CTLA-4 blockade results in an increase in the Teff to Treg ratio (5) (6) (7) . Multiple studies have been conducted to evaluate Tregs in human tumors following anti-CTLA-4 therapy (24-26, 28, 32) . However, most of these studies relied on the evaluation of intratumoral Tregs by flow cytometry with the calculation of FOXP3 + Tregs as a percentage of total cells. In previous studies, FOXP3 + Tregs were evaluated in bladder tumor tissues pre-and post-ipilimumab treatment. We observed an increase in the number of total T cells, but a decrease in frequency of FOXP3 + Tregs, which was measured as a percent of total cells (24, 25) . Since the total number of T cells In the current study, we evaluated immune subsets including CD4 + , CD8 + and FOXP3 + cells in tumor tissues obtained from patients treated with anti-CTLA-4 mAbs by quantitative IHC. We measured the density of T cell subsets in stage-matched human tumor tissues and found that anti-CTLA-4 therapy increases the density of intratumoral CD4 + and CD8 + cells, but without significant change or depletion of FOXP3 + cells. In addition, evaluation of paired pre-treatment and post-ipilimumab treatment melanoma tissues revealed higher densities of intratumoral CD8 + cells (Supplementary Fig. S1B) and FOXP3 + cells ( Supplementary Fig. S1C) .
Importantly, the timing of biopsy collection post-anti-CTLA-4 therapy (ipilimumab and tremelimumab) did not impact the infiltration of immune subsets (Supplementary Fig.   S4 ). Consistent with this, an IHC study evaluating melanoma tumor samples (N=19) demonstrated higher infiltrates of FOXP3 + cells in the responding lesions following treatment with tremelimumab (26) . Taken together, these results indicate that IHC may be a more reliable tool to examine treatment-related changes in immune subsets within the tumor, as it provides a more direct measure of the absolute numbers of cells in a given surface area.
The limitation of single stain IHC is that an individual marker may be expressed on more than one cellular population. For example, single staining for CD8 can represent both T cells and NK cells; likewise, staining for FOXP3 alone can represent Teff and Treg cells.
To address this, we collaborated our IHC results with multiparametric CyTOF analysis of tumor infiltrating cells from paired pre-and post-ipilimumab-treated melanoma tissues. We found that greater than 95% of the CD8 + population were T cells (CD3 + CD8 + );
whereas less than 5% of these were NK cells (CD3 -CD8 + CD56 + ). More importantly, ipilimumab significantly increased the frequency of CD8 + T cells but not CD8 + CD56 + NK cells ( Supplementary Fig. S5) Fig. S6 ).
It has been reported that antibody-mediated depletion can occur via complementmediated lysis (33) or ADCC (5) . In mouse models, the anti-CTLA-4 therapy-mediated depletion of FOXP3 + Treg cells was dependent on the presence of intratumoral FcγRIVexpressing macrophages (5) . In patients, ADCC is essentially mediated through an equivalent FcγR, namely FcγRIIIA (CD16) that is expressed on macrophages and NK cells (27) , which may account for the discrepancy between the preclinical and clinical data. Our findings did not demonstrate significant changes in the intratumoral density of CD68 + macrophages after anti-CTLA-4 therapy; however, we did not evaluate FcγRIIIA expression in these human tumor samples. 
Figure legends
